SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001714899-18-000017
Filing Date
2018-11-08
Accepted
2018-11-08 16:35:23
Documents
3
Period of Report
2018-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a8-k11818.htm 8-K 37155
2 EXHIBIT 99.1 ex991earningsrelease11818.htm EX-99.1 94448
3 logoasjpega06.jpg GRAPHIC 30236
  Complete submission text file 0001714899-18-000017.txt   174568
Mailing Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 181170178
SIC: 2836 Biological Products, (No Diagnostic Substances)
Assistant Director 1